Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

The enhancement of morphine antinociception by a CCKB receptor antagonist in the rat depends on the phase of inflammation and the intensity of carrageenin-induced hyperalgesia

Perrot, Sergea,b; Idänpään-Heikkilä, Juhana Ja,c; Guilbaud, Gisèlea; Kayser, Valériea,*

doi: 10.1016/S0304-3959(97)00178-4

The ability of the cholecystokinin B (CCKB) receptor antagonist L-365,260 to modulate the antinociceptive action of systemic morphine was investigated using the well established rat model of localized inflammation induced by intraplantar injection of carrageenin. The effects of morphine (0.1–1 mg/kg i.v.) alone or in combination with the B receptor antagonist">CCKB receptor antagonist (0.2 mg/kg s.c.) were determined at different time-points (at 1, 3 and 24 h) after the injection of carrageenin by measuring the vocalization threshold to paw pressure. L-365,260 was found to be ineffective in modulating the responses to all doses of morphine at 1 and 24 h after carrageenin. By contrast, at 3 h, the B receptor antagonist">CCKB receptor antagonist reversed the ineffectiveness of the low dose (0.1 mg/kg i.v.) of morphine on the inflamed paw. Further, in the L-365,260-pretreated rats, a significant correlation between the antinociceptive effect of the low dose (0.1 mg/kg) of morphine and the intensity of the mechanical hyperalgesia was observed, indicating that the CCK control of the degree of sensitivity to opioids can vary among the animals. Our data illustrate a differential and limited effect of L-365,260 on opioid antinociception in carrageenin-injected rats, depending on the dose of morphine, the phase of inflammation and the intensity of hyperalgesia.

aUnité de Recherches de Physiopharmacologie du Système Nerveux, I.N.S.E.R.M. U 161, 2 rue d'Alésia, 75014 Paris, France

bService de Rhumatologie et Centre de traitement de la douleur, Hôpital Cochin, 27 Rue du Faubourg St. Jacques, 75014 Paris, France

cInstitute of Biomedicine, Department of Pharmacology and Toxicology, 00014-University of Helsinki, Helsinki, Finland

*Corresponding author. Tel.: +33 1 40789350; fax: +33 1 45881304.

Submitted April 18, 1997; revised October 6, 1997; accepted October 22, 1997.

© Lippincott-Raven Publishers.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website